Sweden’s fastest-growing private biotech, Anocca, has plans for clinical trials in pancreatic cancer using its VIDAR-1 TCR-T cell therapy. Since its inception, the company has raised €100m+ and has formed partnerships with EmendoBio and Shinobi Therapeutics. The company’s CEO, Reagan Jarvis, discusses the evolution of TCR-T therapy, the impact of AI, and their unique approach to treatments.
Critical Kibana Vulnerability Let Attackers Execute Arbitrary Code
Elastic has issued a critical security advisory for Kibana vulnerability CVE-2025-25012, allowing authenticated attackers to execute arbitrary code, scoring 9.9 on the CVSS scale. The
